Asset
OLVIMULOGENE NANIVACIREPVEC
Genelux Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01443260 | phase1_2 | completed | 2012-02-01 | 2014-09-01 | Genelux GmbH | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis |
| NCT05281471 | phase3 | recruiting | 2022-08-31 | 2026-12-01 | Genelux Corporation | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| NCT06463665 | phase2 | recruiting | 2024-09-26 | 2027-02-01 | Genelux Corporation | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
| NCT01584284 | phase1 | completed | 2012-04-01 | 2015-06-01 | Genelux Corporation | Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer |
| NCT00794131 | phase1 | completed | 2008-11-01 | 2015-11-01 | Genelux GmbH | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.